急性心肌梗死后靶向炎症治疗
该综述聚焦急性心肌梗死后炎症反应的多阶段调控机制,指出急性和持续性炎症对再发事件与死亡的预测强于低密度脂蛋白胆固醇。文中评述抗炎治疗作为二级预防策略的临床证据,指出疗效与安全性结果不一致,并强调药物选择、患者筛选和给药时机等关键知识缺口。
要点
- 急性心肌梗死后炎症是残余心血管风险的强预测因子。
- 炎症反应分促炎与修复阶段,调控失常致持续性低度炎症。
- 抗炎治疗证据矛盾,药物选择与时机等关键问题待明确。
核心结论
- 调节炎症是急性心肌梗死后有前景的二级预防策略,但疗效与安全性证据不一,关键知识缺口仍存。
研究设计与样本
- 综述,系统概述急性心肌梗死后炎症机制并评述抗炎治疗用于二级心血管预防的临床证据。
主要发现
- 急性与持续性炎症对再发事件和死亡的预测强于低密度脂蛋白胆固醇。
- 急性心肌梗死后炎症反应为多阶段过程,先促炎阶段后修复阶段,调控失常导致持续性低度炎症和更差临床结局。
- 多种抗炎药物已进入测试,疗效与安全性结果不一致。
临床怎么用
- 综述提示应关注急性心肌梗死后炎症作为残余风险靶点,但药物选择、患者筛选和给药时机尚需进一步证据。
局限性
- 关于潜在类别效应、药物选择、患者选择和最佳给药时机等关键知识缺口仍存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in secondary prevention, adverse cardiovascular events still occur after acute myocardial infarction (AMI). Contributing to residual cardiovascular risk, acute and persistent inflammation is a stronger predictor of recurrent events and mortality than low-density lipoprotein cholesterol. The inflammatory response following AMI is a finely regulated, multiphase process, beginning with a proinflammatory phase followed by a reparative phase. Disruptions in its regulation lead to persistent low-grade inflammation and worse clinical outcomes. Modulating inflammation has emerged as a promising secondary prevention strategy, with several drugs being tested with conflicting results regarding their efficacy and safety. Recently, novel approaches have reignited the interest in anti-inflammatory strategies after AMI. However, key knowledge gaps remain regarding potential class effects, drug choice, patient selection, and the optimal administration timing. This review provides an updated and comprehensive overview of inflammatory mechanisms after AMI and critically appraises the evolving clinical evidence surrounding anti-inflammatory therapies for secondary cardiovascular prevention.
引用
- Imbesi, Greco, Spagnolo, et al. Targeting Inflammation After Acute Myocardial Infarction. J Am Coll Cardiol. 2025. PMID: 41062230. doi:10.1016/j.jacc.2025.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。